SCHEMBL9664111

SCHEMBL9664111

CCCCCCCCCCCCCCCC(=O)N[C@H](C(N)=O)C(C)C

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FAAH O00519 5/20 0.62
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
MAPK1 P28482 1/20 0.62
DNM1 Q05193 1/20 0.56
PLA2G2A P14555 1/20 0.51
PLA2G5 P39877 1/20 0.51
HSP90AA1 P07900 1/20 0.48
PLA2G10 O15496 2/20 0.48
NOD1 Q9Y239 2/20 0.47
PLA2G2C Q5R387 1/20 0.47
ASAH2 Q9NR71 1/20 0.47
ALDH1A1 P00352 1/20 0.46
ASAH1 Q13510 1/20 0.46
ACER2 Q5QJU3 1/20 0.46
SLC6A5 Q9Y345 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9664778 1.00 FAAH (0.62) FAAHMEN1KMT2AMAPK1DNM1
SCHEMBL9665948 1.00 FAAH (0.62) FAAHMEN1KMT2AMAPK1DNM1
SCHEMBL9666504 1.00 FAAH (0.62) FAAHMEN1KMT2AMAPK1DNM1
SCHEMBL9666920 1.00 FAAH (0.62) FAAHMEN1KMT2AMAPK1DNM1
SCHEMBL19933125 1.00 FAAH (0.62) FAAHMEN1KMT2AMAPK1DNM1
SCHEMBL21587883 1.00 FAAH (0.62) FAAHMEN1KMT2AMAPK1DNM1
SCHEMBL18556703 0.98 FAAH (0.59) FAAHMEN1KMT2AMAPK1DNM1
SCHEMBL9664112 0.98 FAAH (0.59) FAAHMEN1KMT2AMAPK1DNM1
SCHEMBL4770925 0.93 FAAH (0.52) FAAHMEN1KMT2AMAPK1DNM1
SCHEMBL21587888 0.91 SLC6A5 (0.57) FAAHMEN1KMT2AASAH2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0473700-A1 AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES NOVO NORDISK A/S (DK) 1992-03-11 EP claimed
WO-1990014429-A1 AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES NOVO NORDISK A/S (DK) 1990-11-29 WO claimed
US-20210230466-A1 PRODUCTS AND METHODS FOR THE TREATMENT OF MIXTURES OF WATER AND HYDROPHOBIC LIQUIDS B.C. RESEARCH INC. (CA) 2021-07-29 US disclosed
WO-2019232629-A1 PRODUCTS AND METHODS FOR THE TREATMENT OF MIXTURES OF WATER AND HYDROPHOBIC LIQUIDS B.C. RESEARCH INC. (CA) 2019-12-12 WO disclosed
EP-0473700-A1 AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES NOVO NORDISK A/S (DK) 1992-03-11 EP disclosed
WO-1990014429-A1 AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES NOVO NORDISK A/S (DK) 1990-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210230466-A1 PRODUCTS AND METHODS FOR THE TREATMENT OF MIXTURES OF WATER AND HYDROPHOBIC LIQUIDS SLC43A1, FABP2, FABP1 FAAH 148/4885MEN1 4306/4885KMT2A 2019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.